Please wait while the formulary information is being retrieved.
SAJAZIR (icatibant acetate)
- inherited disorder of continuing episodes of swelling
- Sajazir Subcutaneous Syringe
- Icatibant Subcutaneous Syringe
- Firazyr Subcutaneous Syringe
- By Indication
30 mg/3 mL subcutaneous syringe
- Inject 3 milliliters (30 mg) by subcutaneous route once, may repeat every 6 hours as needed; do not exceed 3 doses (90 mg) in 24 hours
30 mg/3 mL subcutaneous syringe
- Inject 3 milliliters (30 mg) by subcutaneous route once, may repeat every 6 hours as needed; do not exceed 3 doses (90 mg) in 24 hours
30 mg/3 mL subcutaneous syringe
- Inject 3 milliliters (30 mg) by subcutaneous route once, may repeat every 6 hours as needed; do not exceed 3 doses (90 mg) in 24 hours
Hereditary angioedema
- Inject 3 milliliters (30 mg) by subcutaneous route once, may repeat every 6 hours as needed; do not exceed 3 doses (90 mg) in 24 hours
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- None
Severe
Moderate
- No disease contraindications
SAJAZIR (icatibant acetate)
- inherited disorder of continuing episodes of swelling
- None
- Injection site erythema
- Injection site sequelae
More Frequent
Severe
Less Severe
- Abnormal hepatic function tests
- Hypersensitivity drug reaction
- Abdominal distension
- Diarrhea
- Dizziness
- Fatigue
- Fever
- Headache disorder
- Nasal congestion
- Nausea
- Pharyngitis
- Pruritus of skin
- Sinusitis
- Skin rash
- Urinary tract infection
- Xerostomia
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Cardiac arrhythmia
- Increased alanine transaminase
- Increased aspartate transaminase
- Laryngeal edema
Less Severe
- Non-cardiac chest pain
- Urticaria
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Icatibant
Potential risk of delayed sexual maturity in males. Safety and efficacy not established.
- 1 Day – 18 Years
- Potential risk of delayed sexual maturity in males. Safety and efficacy not established.
Icatibant
- Severity Level:
2
- Additional Notes: Insufficient human data available on developmental toxicity risk.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Icatibant
Insufficient human data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Hereditary angioedema | |
| D84.1 | Defects in the complement system |
| 0-9 | A-Z |
|---|---|
| D84.1 | Defects in the complement system |
Formulary Reference Tool